BMS, Lundbeck execs jump ship

Two C-level execs abruptly exited their respective buildings this week. Danish drug maker Lundbeck lost its CEO Claus Braestrup yesterday when he announced he would resign immediately. The 63-year-old had said he planned to leave after announcing 2007 results, but officials didn't expect him to take a flyer. "It is regrettable that Claus Braestrup has decided to resign from his position sooner than we had expected," a board member said. No kidding: The company just posted its best financial performance ever.

Meanwhile, Bristol-Myers Squibb's executive VP and CFO Andrew Bonfield will leave the company "to seek new career opportunities;" he'll be replaced by Jean-Marc Huet, CFO at Amsterdam's Royal Numico, where he engineered some acquisitions. Bonfield will stick around to help Huet make the transition. In a news release, CEO Jim Cornelius (photo) stated that Bonfield ID'd Huet as a potential successor last year. A company spokeswoman told Pharmalot that Bonfield's departure is "completely unrelated" to a $275 million charge on subprime securities losses, though the corporate treasurer and controller was a casualty. "He's been talking to Jim since 2007 about his role and career plans," the spokeswoman said.

- see Lundbeck's press release
- read the release from Bristol-Myers
- check out Pharmalot's coverage here and here

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.